|
ES2524356T3
(es)
|
2010-07-22 |
2014-12-05 |
Gilead Sciences, Inc. |
Métodos y compuestos para tratar infecciones provocadas por virus Paramyxoviridae
|
|
EP2545964A1
(en)
|
2011-07-13 |
2013-01-16 |
Phenex Pharmaceuticals AG |
Novel FXR (NR1H4) binding and activity modulating compounds
|
|
CN115990171A
(zh)
*
|
2014-09-28 |
2023-04-21 |
华辉安健（北京）生物科技有限公司 |
聚合胆汁酸衍生物抑制乙型肝炎病毒和丁型肝炎病毒和ntcp运输
|
|
TWI740546B
(zh)
|
2014-10-29 |
2021-09-21 |
美商基利科學股份有限公司 |
製備核糖苷的方法
|
|
TWI698430B
(zh)
|
2015-02-13 |
2020-07-11 |
南北兄弟藥業投資有限公司 |
三環化合物及其在藥物中的應用
|
|
WO2016161003A1
(en)
|
2015-03-31 |
2016-10-06 |
Enanta Phamraceuticals, Inc. |
Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
|
|
PE20180690A1
(es)
*
|
2015-04-27 |
2018-04-23 |
Intercept Pharmaceuticals Inc |
Composiciones de acido obeticolico y metodos de uso
|
|
HRP20220355T1
(hr)
|
2015-09-16 |
2022-05-13 |
Gilead Sciences, Inc. |
Postupci za liječenje infekcija coronaviridae
|
|
WO2017189663A1
(en)
|
2016-04-26 |
2017-11-02 |
Enanta Pharmaceuticals, Inc. |
Isoxazole derivatives as fxr agonists and methods of use thereof
|
|
US10080742B2
(en)
|
2016-04-26 |
2018-09-25 |
Enanta Pharmaceuticals, Inc. |
Isoxazole derivatives as FXR agonists and methods of use thereof
|
|
WO2017189652A1
(en)
|
2016-04-26 |
2017-11-02 |
Enanta Pharmaceuticals, Inc. |
Isoxazole derivatives as fxr agonists and methods of use thereof
|
|
WO2017201155A1
(en)
*
|
2016-05-18 |
2017-11-23 |
Enanta Pharmaceuticals, Inc. |
lSOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF
|
|
WO2017201152A1
(en)
*
|
2016-05-18 |
2017-11-23 |
Enanta Pharmaceuticals, Inc. |
Isoxazole derivatives as fxr agonists and methods of use thereof
|
|
US10144729B2
(en)
|
2016-05-18 |
2018-12-04 |
Enanta Pharmaceuticals, Inc. |
Isoxazole analogs as FXR agonists and methods of use thereof
|
|
CA3252823A1
(en)
|
2016-06-13 |
2025-02-25 |
Gilead Sciences, Inc. |
Substituted tert-butyl-3-(2-chloro-phenyl)-3-hydroxyazetidine-1-carboxylate compounds
|
|
BR112018075734A2
(pt)
|
2016-06-13 |
2019-04-02 |
Gilead Sciences, Inc. |
composto, composição farmacêutica, método para tratar um paciente com uma doença ou condição mediada pelo menos em parte por fxr, e, uso de um composto.
|
|
WO2018045150A1
(en)
|
2016-09-02 |
2018-03-08 |
Gilead Sciences, Inc. |
4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
|
|
MA46093A
(fr)
|
2016-09-02 |
2021-05-19 |
Gilead Sciences Inc |
Composés modulateurs du recepteur de type toll
|
|
US10588880B2
(en)
*
|
2016-09-28 |
2020-03-17 |
Eiger Biopharmaceuticals, Inc. |
Methods and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitis
|
|
WO2018067704A1
(en)
|
2016-10-04 |
2018-04-12 |
Enanta Pharmaceuticals, Inc. |
Isoxazole analogs as fxr agonists and methods of use thereof
|
|
FI3526323T3
(fi)
|
2016-10-14 |
2023-06-06 |
Prec Biosciences Inc |
Hepatiitti B -viruksen genomissa oleville tunnistussekvensseille spesifisiä muokattuja meganukleaaseja
|
|
US10597391B2
(en)
|
2016-10-26 |
2020-03-24 |
Enanta Pharmaceuticals, Inc. |
Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof
|
|
CN108017636A
(zh)
*
|
2016-11-04 |
2018-05-11 |
合帕吉恩治疗公司 |
作为fxr调节剂的含氮杂环化合物
|
|
AR110768A1
(es)
|
2017-01-31 |
2019-05-02 |
Gilead Sciences Inc |
Formas cristalinas de tenofovir alafenamida
|
|
CN116036112A
(zh)
|
2017-03-14 |
2023-05-02 |
吉利德科学公司 |
治疗猫冠状病毒感染的方法
|
|
CN110461328A
(zh)
|
2017-03-28 |
2019-11-15 |
吉利德科学公司 |
治疗肝疾病的治疗组合
|
|
US20210085662A1
(en)
*
|
2017-03-30 |
2021-03-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for reducing persistence and expression of episomal viruses
|
|
BR102018007822A2
(pt)
|
2017-04-20 |
2018-11-06 |
Gilead Sciences, Inc. |
composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
|
|
WO2018204198A1
(en)
|
2017-05-01 |
2018-11-08 |
Gilead Sciences, Inc. |
Crystalline forms of (s) 2 ethylbutyl 2 (((s) (((2r,3s,4r,5r) 5 (4 aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2 yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
|
|
EP4512475A3
(en)
|
2017-07-11 |
2025-05-14 |
Gilead Sciences, Inc. |
Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections
|
|
KR102114394B1
(ko)
|
2017-08-30 |
2020-05-22 |
경희대학교 산학협력단 |
벤조페논 유도체, 이의 제조방법 및 이를 포함하는 b형간염 치료용 약학적 조성물
|
|
US10689391B2
(en)
|
2017-12-12 |
2020-06-23 |
Enanta Pharmaceuticals, Inc. |
Isoxazole analogs as FXR agonists and methods of use thereof
|
|
JP7098748B2
(ja)
|
2017-12-20 |
2022-07-11 |
インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． |
Ｓｔｉｎｇアダプタータンパク質を活性化するホスホン酸結合を有する２’３’環状ジヌクレオチド
|
|
KR102492187B1
(ko)
|
2017-12-20 |
2023-01-27 |
인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. |
Sting 어댑터 단백질을 활성화하는 포스포네이트 결합을 가진 3'3' 사이클릭 다이뉴클레오티드
|
|
CN110128432B
(zh)
|
2018-02-02 |
2021-03-02 |
广东东阳光药业有限公司 |
含氮三环化合物及其在药物中的应用
|
|
KR102708681B1
(ko)
|
2018-02-13 |
2024-09-26 |
길리애드 사이언시즈, 인코포레이티드 |
Pd-1/pd-l1 억제제
|
|
US10829486B2
(en)
|
2018-02-14 |
2020-11-10 |
Enanta Pharmacueticals, Inc. |
Isoxazole derivatives as FXR agonists and methods of use thereof
|
|
KR102526964B1
(ko)
|
2018-02-26 |
2023-04-28 |
길리애드 사이언시즈, 인코포레이티드 |
Hbv 복제 억제제로서의 치환된 피롤리진 화합물
|
|
US10870691B2
(en)
|
2018-04-05 |
2020-12-22 |
Gilead Sciences, Inc. |
Antibodies and fragments thereof that bind hepatitis B virus protein X
|
|
TW202005654A
(zh)
|
2018-04-06 |
2020-02-01 |
捷克科學院有機化學與生物化學研究所 |
２，２，─環二核苷酸
|
|
TWI818007B
(zh)
|
2018-04-06 |
2023-10-11 |
捷克科學院有機化學與生物化學研究所 |
2'3'-環二核苷酸
|
|
TWI833744B
(zh)
|
2018-04-06 |
2024-03-01 |
捷克科學院有機化學與生物化學研究所 |
3'3'-環二核苷酸
|
|
TW201945388A
(zh)
|
2018-04-12 |
2019-12-01 |
美商精密生物科學公司 |
對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶
|
|
EP4600247A3
(en)
|
2018-04-19 |
2025-11-19 |
Gilead Sciences, Inc. |
Pd-1/pd-l1 inhibitors
|
|
US20190359645A1
(en)
|
2018-05-03 |
2019-11-28 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
|
|
UA126421C2
(uk)
|
2018-07-13 |
2022-09-28 |
Гіліад Сайєнсіз, Інк. |
Інгібітори pd-1/pd-l1
|
|
WO2020028097A1
(en)
|
2018-08-01 |
2020-02-06 |
Gilead Sciences, Inc. |
Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
|
|
US11236085B2
(en)
|
2018-10-24 |
2022-02-01 |
Gilead Sciences, Inc. |
PD-1/PD-L1 inhibitors
|
|
PE20211655A1
(es)
|
2018-10-31 |
2021-08-24 |
Gilead Sciences Inc |
Compuestos de 6-azabencimidazol sustituidos como inhibidores de hpk1
|
|
WO2020092528A1
(en)
|
2018-10-31 |
2020-05-07 |
Gilead Sciences, Inc. |
Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
|
|
EP4360632B1
(en)
|
2019-01-15 |
2025-10-29 |
Gilead Sciences, Inc. |
Fxr (nr1h4) modulating compounds
|
|
US11524005B2
(en)
|
2019-02-19 |
2022-12-13 |
Gilead Sciences, Inc. |
Solid forms of FXR agonists
|
|
WO2020178768A1
(en)
|
2019-03-07 |
2020-09-10 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
|
|
WO2020178770A1
(en)
|
2019-03-07 |
2020-09-10 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3'-cyclic dinucleotides and prodrugs thereof
|
|
CN113543851B
(zh)
|
2019-03-07 |
2025-03-18 |
捷克共和国有机化学与生物化学研究所 |
2’3’-环二核苷酸及其前药
|
|
TW202210480A
(zh)
|
2019-04-17 |
2022-03-16 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
TW202104210A
(zh)
|
2019-04-17 |
2021-02-01 |
美商基利科學股份有限公司 |
Hiv蛋白酶抑制劑
|
|
TW202212339A
(zh)
|
2019-04-17 |
2022-04-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
WO2020231917A1
(en)
|
2019-05-13 |
2020-11-19 |
Enanta Pharmaceuticals, Inc. |
Isoxazole derivatives as fxr agonists and methods of use thereof
|
|
TWI826690B
(zh)
|
2019-05-23 |
2023-12-21 |
美商基利科學股份有限公司 |
經取代之烯吲哚酮化物及其用途
|
|
AU2020301161B2
(en)
|
2019-06-25 |
2023-10-26 |
Gilead Sciences, Inc. |
FLT3L-Fc fusion proteins and methods of use
|
|
WO2021011891A1
(en)
|
2019-07-18 |
2021-01-21 |
Gilead Sciences, Inc. |
Long-acting formulations of tenofovir alafenamide
|
|
EP3999069B1
(en)
*
|
2019-07-18 |
2023-10-11 |
ENYO Pharma |
Synergistic effect of eyp001 and pegylated ifn-alpha for the treatment of hbv infection
|
|
AU2020312735A1
(en)
*
|
2019-07-18 |
2021-12-16 |
Enyo Pharma |
Method for decreasing adverse-effects of interferon
|
|
AU2020312734B2
(en)
*
|
2019-07-18 |
2025-11-20 |
Enyo Pharma |
Improved treatment using EYP001
|
|
WO2021034804A1
(en)
|
2019-08-19 |
2021-02-25 |
Gilead Sciences, Inc. |
Pharmaceutical formulations of tenofovir alafenamide
|
|
EP4458975A3
(en)
|
2019-09-30 |
2025-02-12 |
Gilead Sciences, Inc. |
Hbv vaccines and methods treating hbv
|
|
WO2021108974A1
(en)
|
2019-12-03 |
2021-06-10 |
Gannex Pharma Co., Ltd |
Compounds for modulating activity of fxr and uses thereof
|
|
ES3022990T3
(en)
|
2019-12-06 |
2025-05-29 |
Prec Biosciences Inc |
Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
|
|
EP4445902A3
(en)
|
2019-12-24 |
2024-12-18 |
Carna Biosciences, Inc. |
Diacylglycerol kinase modulating compounds
|
|
US20230060715A1
(en)
*
|
2020-01-15 |
2023-03-02 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of fxr agonists for treating an infection by hepatitis d virus
|
|
AU2021214911A1
(en)
|
2020-01-27 |
2022-07-21 |
Gilead Sciences, Inc. |
Methods for treating SARS CoV-2 infections
|
|
CN118994170A
(zh)
|
2020-03-12 |
2024-11-22 |
吉利德科学公司 |
制备1'-氰基核苷的方法
|
|
MX2022011582A
(es)
|
2020-03-18 |
2022-12-13 |
Metacrine Inc |
Formas cristalinas de un agonista del receptor farnesoide x.
|
|
BR112022018553A2
(pt)
|
2020-03-18 |
2022-11-29 |
Metacrine Inc |
Formulações de um agonista do receptor x farnesoide
|
|
CA3169348A1
(en)
|
2020-03-20 |
2021-09-23 |
Gilead Sciences, Inc. |
Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
|
|
EP4132651B1
(en)
|
2020-04-06 |
2026-03-18 |
Gilead Sciences, Inc. |
Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
|
|
KR20200049728A
(ko)
|
2020-04-24 |
2020-05-08 |
경희대학교 산학협력단 |
벤조페논 유도체, 이의 제조방법 및 이를 포함하는 b형간염 치료용 약학적 조성물
|
|
ES3041698T3
(en)
|
2020-05-29 |
2025-11-13 |
Gilead Sciences Inc |
Remdesivir for the treatment of viral infections
|
|
CA3187821A1
(en)
|
2020-06-24 |
2021-12-30 |
Gilead Sciences, Inc. |
1'-cyano nucleoside analogs and uses thereof
|
|
ES3054072T3
(en)
|
2020-08-07 |
2026-01-29 |
Gilead Sciences Inc |
Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use
|
|
MX2023002233A
(es)
|
2020-08-24 |
2023-03-15 |
Gilead Sciences Inc |
Compuestos fosfolipidos y usos de estos.
|
|
WO2022047065A2
(en)
|
2020-08-27 |
2022-03-03 |
Gilead Sciences, Inc. |
Compounds and methods for treatment of viral infections
|
|
WO2022076683A1
(en)
*
|
2020-10-07 |
2022-04-14 |
Intercept Pharmaceuticals, Inc. |
Methods of treating coronaviral infection with obeticholic acid
|
|
TWI811812B
(zh)
|
2020-10-16 |
2023-08-11 |
美商基利科學股份有限公司 |
磷脂化合物及其用途
|
|
TW202406932A
(zh)
|
2020-10-22 |
2024-02-16 |
美商基利科學股份有限公司 |
介白素2-Fc融合蛋白及使用方法
|
|
CN116685321A
(zh)
*
|
2021-01-14 |
2023-09-01 |
埃尼奥制药公司 |
治疗慢性肾病的方法
|
|
US20240100125A1
(en)
*
|
2021-01-14 |
2024-03-28 |
Enyo Pharma |
Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection
|
|
EP4324825A4
(en)
*
|
2021-04-16 |
2025-08-27 |
Beijing Best Pathway Man Consulting Center Limited Partnership |
FXR REGULATOR, ITS PREPARATION METHOD, PHARMACEUTICAL COMPOSITION THEREOF AND ITS USE
|
|
AU2022274607A1
(en)
|
2021-05-13 |
2023-11-16 |
Gilead Sciences, Inc. |
COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
|
|
WO2022251318A1
(en)
|
2021-05-26 |
2022-12-01 |
Gilead Sciences, Inc. |
Phospholipid formulations of 1'-cyano substituted carba-nucleoside analogs
|
|
WO2022271650A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
US11932634B2
(en)
|
2021-06-23 |
2024-03-19 |
Gilead Sciences, Inc. |
Diacylglycerol kinase modulating compounds
|
|
WO2022271659A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
EP4359415A1
(en)
|
2021-06-23 |
2024-05-01 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
JP7719954B2
(ja)
|
2021-08-18 |
2025-08-06 |
ギリアード サイエンシーズ， インコーポレイテッド |
リン脂質化合物並びにその製造方法及び使用方法
|
|
JP2025014084A
(ja)
*
|
2021-12-07 |
2025-01-29 |
慶應義塾 |
ウイルス増殖抑制剤
|
|
EP4486746A1
(en)
|
2022-03-02 |
2025-01-08 |
Gilead Sciences, Inc. |
Compounds and methods for treatment of viral infections
|
|
TW202525810A
(zh)
|
2022-03-02 |
2025-07-01 |
美商基利科學股份有限公司 |
用於治療病毒感染的化合物及方法
|
|
WO2023168254A1
(en)
|
2022-03-03 |
2023-09-07 |
Gilead Sciences, Inc. |
Antiviral compounds and methods of making and using the same
|
|
CR20240367A
(es)
|
2022-03-03 |
2024-09-30 |
Gilead Sciences Inc |
Compuestos antivirales y métodos de elaboración y uso de los mismos.
|
|
WO2023195798A1
(ko)
*
|
2022-04-06 |
2023-10-12 |
(주)샤페론 |
타우로데옥시콜린산 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 폐섬유증 예방 또는 치료용 조성물
|
|
CN119604286A
(zh)
|
2022-06-06 |
2025-03-11 |
吉利德科学公司 |
用于治疗包括sars-cov-2的病毒感染的方法
|
|
WO2024006376A1
(en)
|
2022-06-29 |
2024-01-04 |
Gilead Sciences, Inc. |
Solid forms of a nucleoside analogue and uses thereof
|
|
WO2024006461A1
(en)
|
2022-06-30 |
2024-01-04 |
Gilead Sciences, Inc. |
Solid forms of a nucleoside analogue and uses thereof
|
|
US12357577B1
(en)
|
2024-02-02 |
2025-07-15 |
Gilead Sciences, Inc. |
Pharmaceutical formulations and uses thereof
|
|
EP4665737A1
(en)
|
2023-02-16 |
2025-12-24 |
Gilead Sciences, Inc. |
Phospholipid compounds and methods of making and using the same
|
|
CN121693506A
(zh)
|
2023-08-31 |
2026-03-17 |
吉利德科学公司 |
抗病毒化合物及其制备和使用方法
|
|
US20250090537A1
(en)
|
2023-08-31 |
2025-03-20 |
Gilead Sciences, Inc. |
Antiviral compounds and methods of making and using the same
|
|
WO2025054278A1
(en)
|
2023-09-06 |
2025-03-13 |
Gilead Sciences, Inc. |
Solid forms of a nucleoside analogue and uses thereof
|
|
US20250109157A1
(en)
|
2023-09-28 |
2025-04-03 |
Gilead Sciences, Inc. |
Compounds and methods for treatment of viral infections
|
|
WO2025240243A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus
|
|
WO2025240246A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies with ribavirin
|
|
WO2025240244A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection
|
|
WO2025240242A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies with ribavirin
|